Sensyne Health: Annual Report and Accounts and Notice of Annual General Meeting

Sensyne Health plc, the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors.

Oxford, UK; 07 October 2019: Sensyne Health plc (LSE: SENS) (the “Company”), the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors. Copies of the Annual Report and Accounts will be also posted to those shareholders that have elected to receive paper communications.

The Company also announces that its Notice of Annual General Meeting has been posted to shareholders today. The Annual General Meeting will be held at the offices of Allen & Overy LLP at One Bishops Square, London E1 6AD United Kingdom on Wednesday 30 October at 11:00 am (London time). The doors will open at 10.30 am.

For more information please contact:

Sensyne Health (www.sensynehealth.com) +44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) + 44 (0)20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications +44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

MORE ON THIS TOPIC